Latest news with #DOSE
Zawya
10-04-2025
- Business
- Zawya
AkamAlRajhi appoints U Hotels to manage 5-star hotel and serviced units on the North Coast
Saudi-Egyptian joint venture AkamAlRajhi Developments announced on Thursday that it has appointed Thailand-based global hotel operator U Hotels & Resorts to manage a new 5-star hotel located within their DOSE project on the North Coast, and the 1,000 unit JAY By U serviced units in the same project. Company CEO Edrees Mohamed told Zawya Projects that the 120-key U hotel, which is being developed at a total cost of 1.2 billion Egyptian pounds ($23 million) will open its doors by 2029. Mohamed Amer, Head of the Central Administration for Hotel Establishments, Shops, and Tourism Activities at the Ministry of Tourism, said the Egyptian government aims to double the hotel rooms in the country from existing 230,000 units in the next five years as part of its strategy to welcome three millon tourists by 2030. AkamAlRajhi Developments, a joint venture between Egypt's Akam Developments and Saudi's AlRajhi Group, launched the DOSE project in 2022. The 125-acre project, which is scheduled to be completed in four phases, includes chalets, standalone villas, twin-townhouses, and serviced units. Cairo-based K&D Designs and United States-based SB Architects are the architectural consultants for the project. In 2023, AkamAlRajhi Developments had appointed global hotel operator IHG Hotels & Resorts to manage its first 5-star hotel located within the DOSE project. Edrees Mohamed said that they are planning a new project in Riyadh in Saudi Arabia in collaboration with Saudi National Housing Comany (NHC) but didn't elaborate. (Reporting by Eman Hamed; Editing by Anoop Menon)
Associated Press
06-02-2025
- Business
- Associated Press
Innovation Zed and Glooko Partner to Revolutionize Injectable Therapy Management with Digital Companion Apps
DUBLIN, IE / ACCESS Newswire / February 6, 2025 / Glooko, Inc., a global integrated digital health company connecting patients, providers, biopharma, and medical device partners, and Innovation Zed, a pioneering developer of connected add-on devices for drug delivery devices, today announced a strategic partnership to develop and deploy digital companion apps with the adaptive DOSE platform hardware add-on technology for injectable therapies. This collaboration aims to revolutionize the management of injectable medications by providing comprehensive connectivity and data capture solutions for dosing, storage, and injection Zed Logo Addressing the Challenges of Injectable Therapies Injectable therapies are essential for managing many chronic conditions, yet they pose significant challenges. Complex dosing regimens, fear of injections, and variability in injection technique can hinder adherence and compromise safety. Additionally, improper storage can impact medication efficacy, while limited data capture makes it difficult to monitor patient progress effectively. This collaboration aims to address these challenges by providing a comprehensive digital solution that supports patients and healthcare providers in optimizing injectable therapies. Glooko and Innovation Zed's Innovative Technology This innovative digital companion system, seamlessly integrating hardware and software, will be designed to integrate with the Glooko platform, currently used by over 8,200 diabetes clinics worldwide. This integration will enable the capture and analysis of critical information related to injectable therapies from Innovation Zed's DOSE platform technology, offering enhanced support for healthcare providers and patients alike. Key Benefits of the Digital Companion Apps: Improved Adherence: Accurate recording and monitoring of dosing schedules to support adherence and optimize therapy outcomes. Enhanced Safety: Guidance on proper storage conditions to maintain medication efficacy and educational resources on correct injection techniques. Increased Patient Confidence: Support and feedback on injection techniques to improve patient confidence and safety. Streamlined Data Management: Real-time data capture and connectivity for a wide range of injectable medications, providing valuable insights for healthcare professionals. Expanding Access and Gathering Real-World Data By leveraging the extensive reach of the Glooko platform, this partnership offers industry partners a valuable launchpad into key markets, enhancing the accessibility and effectiveness of injectable therapies globally. This constitutes a unique opportunity for the pharmaceutical industry to gather valuable real-world data in real-time, leading to a deeper understanding of patient behavior. 'We are excited to partner with Innovation Zed to bring this cutting-edge digital companion system to market,' said Mike Alvarez, Chief Executive Officer of Glooko. 'This collaboration will enable us to provide comprehensive support for patients and their healthcare providers, ultimately enhancing the treatment experience and improving outcomes. This partnership, combined with our ongoing platform development, reflects Glooko's continued focus on increasing the benefits delivered to patients and clinics.' 'Our partnership with Glooko represents a significant step forward in the integration of our smart drug delivery solutions with a leading digital health platform,' said Dr. Dean Minnock, Chief Executive Officer of Innovation Zed. 'Together, we can offer unparalleled support to patients and healthcare providers, improving the management of injectable therapies worldwide.' About Glooko Glooko improves health outcomes of people with chronic conditions through personalized, intelligent, connected care and life sciences platforms. Our proven technologies make lives better by revolutionizing the connection between patients and providers, driving patient engagement and adherence via digital therapeutics, and accelerating the speed of clinical trials. Glooko solutions are globally deployed in more than 30 countries, 10,000+ clinical locations* and partner to connect with over 200 devices. With more than 4.4 million people worldwide who have used Glooko platforms, Glooko boasts the largest installed base of patients living with diabetes. For more information, please visit About Innovation Zed Innovation Zed is a leading provider of connected health solutions, specializing in developing innovative medical devices to support drug adherence and diabetes management. With a focus on leveraging technology to enhance patient outcomes, Innovation Zed continues to pioneer new methods for personalized condition management and improved drug adherence. Visit to learn more. Contact: Glooko Media Relations Phone: +353 (1) 437-0331 *This count indicates the number of health clinics that have registered and uploaded health data over the 14 year period with one of the Glooko solutions, which are the Glooko® System, Glooko XT®, and diasend® System.
Yahoo
06-02-2025
- Business
- Yahoo
Innovation Zed and Glooko Partner to Revolutionize Injectable Therapy Management with Digital Companion Apps
DUBLIN, IE / / February 6, 2025 / Glooko, Inc., a global integrated digital health company connecting patients, providers, biopharma, and medical device partners, and Innovation Zed, a pioneering developer of connected add-on devices for drug delivery devices, today announced a strategic partnership to develop and deploy digital companion apps with the adaptive DOSE platform hardware add-on technology for injectable therapies. This collaboration aims to revolutionize the management of injectable medications by providing comprehensive connectivity and data capture solutions for dosing, storage, and injection techniques. Addressing the Challenges of Injectable Therapies Injectable therapies are essential for managing many chronic conditions, yet they pose significant challenges. Complex dosing regimens, fear of injections, and variability in injection technique can hinder adherence and compromise safety. Additionally, improper storage can impact medication efficacy, while limited data capture makes it difficult to monitor patient progress effectively. This collaboration aims to address these challenges by providing a comprehensive digital solution that supports patients and healthcare providers in optimizing injectable therapies. Glooko and Innovation Zed's Innovative Technology This innovative digital companion system, seamlessly integrating hardware and software, will be designed to integrate with the Glooko platform, currently used by over 8,200 diabetes clinics worldwide. This integration will enable the capture and analysis of critical information related to injectable therapies from Innovation Zed's DOSE platform technology, offering enhanced support for healthcare providers and patients alike. Key Benefits of the Digital Companion Apps: Improved Adherence: Accurate recording and monitoring of dosing schedules to support adherence and optimize therapy outcomes. Enhanced Safety: Guidance on proper storage conditions to maintain medication efficacy and educational resources on correct injection techniques. Increased Patient Confidence: Support and feedback on injection techniques to improve patient confidence and safety. Streamlined Data Management: Real-time data capture and connectivity for a wide range of injectable medications, providing valuable insights for healthcare professionals. Expanding Access and Gathering Real-World Data By leveraging the extensive reach of the Glooko platform, this partnership offers industry partners a valuable launchpad into key markets, enhancing the accessibility and effectiveness of injectable therapies globally. This constitutes a unique opportunity for the pharmaceutical industry to gather valuable real-world data in real-time, leading to a deeper understanding of patient behavior. "We are excited to partner with Innovation Zed to bring this cutting-edge digital companion system to market," said Mike Alvarez, Chief Executive Officer of Glooko. "This collaboration will enable us to provide comprehensive support for patients and their healthcare providers, ultimately enhancing the treatment experience and improving outcomes. This partnership, combined with our ongoing platform development, reflects Glooko's continued focus on increasing the benefits delivered to patients and clinics." "Our partnership with Glooko represents a significant step forward in the integration of our smart drug delivery solutions with a leading digital health platform," said Dr. Dean Minnock, Chief Executive Officer of Innovation Zed. "Together, we can offer unparalleled support to patients and healthcare providers, improving the management of injectable therapies worldwide." About Glooko Glooko improves health outcomes of people with chronic conditions through personalized, intelligent, connected care and life sciences platforms. Our proven technologies make lives better by revolutionizing the connection between patients and providers, driving patient engagement and adherence via digital therapeutics, and accelerating the speed of clinical trials. Glooko solutions are globally deployed in more than 30 countries, 10,000+ clinical locations* and partner to connect with over 200 devices. With more than 4.4 million people worldwide who have used Glooko platforms, Glooko boasts the largest installed base of patients living with diabetes. For more information, please visit About Innovation Zed Innovation Zed is a leading provider of connected health solutions, specializing in developing innovative medical devices to support drug adherence and diabetes management. With a focus on leveraging technology to enhance patient outcomes, Innovation Zed continues to pioneer new methods for personalized condition management and improved drug adherence. Visit to learn more. Contact: Glooko Media RelationsEmail: pr@ +1 (800) 206-6601 Innovation Zed Media RelationsEmail: pr@ +353 (1) 437-0331 *This count indicates the number of health clinics that have registered and uploaded health data over the 14 year period with one of the Glooko solutions, which are the Glooko® System, Glooko XT®, and diasend® System. Contact Information Dean Minnock CEOpr@ (1) 437-0331 Andrew Fitzpatrick Research and Innovations Managerandrewf@ SOURCE: Innovation Zed Ltd. View the original press release on ACCESS Newswire Sign in to access your portfolio
